Clinical Trial Update: A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC [Phase 2]

View source ↗

Summary

Phase II clinical trial update exploring predictive factors for TX and XELOX regimens as first-line treatment in gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• TX

Snippet

Sponsor: Fudan University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN